Regulatory Education for Industry (REdI) Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products - 05/19/2026

Why It Matters

The conference equips regulatory professionals with up‑to‑date guidance, helping companies accelerate product approvals while maintaining compliance, a critical advantage in today’s fast‑moving medical‑technology market.

Key Takeaways

• Three tracks cover drugs, devices, biologics.
• AI and digital health featured in sessions.
• Up to 12 RAPS credits available.
• Both virtual and in‑person attendance options.
• FDA resources linked for post‑conference reference.

Pulse Analysis

The REdI Annual Conference arrives at a pivotal moment for the life‑science sector, as regulators and innovators grapple with rapid technological change. By convening experts from CDER, CDRH, and CBER, the FDA provides a rare platform where emerging topics—such as artificial intelligence in drug discovery, digital health tools for clinical trials, and updated quality‑management system requirements—are dissected in real time. Participants gain actionable insights that go beyond static guidance documents, positioning them to integrate cutting‑edge science while adhering to evolving compliance standards.

Beyond knowledge transfer, the event’s continuing‑education component delivers tangible career value. Professionals can secure up to 12 RAPS credits, SOCRA documentation, SQA units, and ACRP contact hours, all of which count toward mandatory recertification. This dual focus on technical depth and credentialing makes the conference a strategic investment for individuals and organizations alike, fostering a workforce that can navigate complex submission pathways for INDs, NDAs, BLAs, PMAs, and device clearances. Networking opportunities—both virtual and in‑person—further amplify the benefit, enabling cross‑disciplinary dialogue that can spark collaborative solutions.

For companies, the conference serves as a roadmap for aligning product pipelines with the FDA’s latest expectations. Leveraging the linked FDA resources, firms can streamline pre‑submission planning, reduce review cycles, and mitigate regulatory risk. As the industry leans into advanced therapies, AI‑enhanced manufacturing, and real‑world evidence, staying attuned to REdI’s curriculum becomes a competitive differentiator, ensuring that innovative medical products reach patients efficiently and safely.